Our findings indicate that therapeutic intervention at the vasculature level, such as the regulation of vascular permeability, can be effective in the treatment of AD, and that the VEGFR-2-specific antagonist Ac-RLYE might be a promising and safe candidate for treating AD. Here, KDR is linked to Alzheimer disease.